- Riverstone (SGX:AP4) is set to benefit from the higher US tariffs on China’s gloves as it will ease the competition in the healthcare glove and lower-tier cleanroom glove industries. The US market’s contribution to Riverstone’s total revenue, which was 18% in 2023, could rise when the tariff starts.
- - Read this at SGinvestors.io -
Higher US tariffs on China’s medical and surgical gloves from 2026.
- US President Joe Biden announced new tariffs on US$18b worth of Chinese imports, including rubber medical and surgical gloves, among others, on Tuesday. The current 7.5% tariff on China’s glove exports will more than triple to a steep 25% and will take effect from 2026.
Anticipating a shift in business landscape.
- - Read this at SGinvestors.io -
- For Riverstone, the emergence of China players has impacted the demand for its healthcare gloves and the lower tiers of its cleanroom gloves.
Riverstone to benefit from potential higher US demand.
- Read more at SGinvestors.io.
Above is the excerpt from report by UOB Kay Hian Research.
Clients of UOB Kay Hian may be the first to access the full report in PDF @ https://www.utrade.com.sg/.
John Cheong UOB Kay Hian Research | Heidi Mo UOB Kay Hian | https://research.uobkayhian.com/ 2024-05-16
Read also UOB's most recent report:
2024-11-13 Riverstone - 3Q24 Results In Line; Healthy Outlook Ahead With Capacity Expansion.
Previous report by UOB:
2024-07-25 Riverstone - Strong Earnings Expected; Target Price Raised To S$1.16.
Price targets by 3 other brokers at Riverstone Target Prices.
Listing of research reports at Riverstone Analyst Reports.
Relevant links:
Riverstone Share Price History,
Riverstone Announcements,
Riverstone Dividends & Corporate Actions,
Riverstone News Articles
